Tuesday, September 23, 2025
News Health
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health
No Result
View All Result
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health
No Result
View All Result
HealthNews
No Result
View All Result
Home Health News

TNF Inhibitors Linked to Lower PsA Risk in Severe Psoriasis

July 14, 2025
in Health News
Share on FacebookShare on Twitter


TOPLINE:

In patients with chronic plaque psoriasis, long-term treatment with TNF inhibitors was associated with a lower risk for psoriatic arthritis (PsA) than narrow-band ultraviolet B phototherapy.

METHODOLOGY:

  • In a longitudinal cohort study, researchers included 946 adult patients treated for chronic plaque psoriasis between September 2005 and September 2010.
  • Two propensity score-matched groups with 297 patients each were formed: those who received TNF inhibitors, including etanercept, infliximab, and adalimumab (mean age, 52.2 years; 65.7% men), and phototherapy using narrow-band ultraviolet B (mean age, 51.5 years; 64.6% men).
  • Patients underwent a rheumatologist assessment before therapy initiation.
  • The incidence of PsA was assessed over a mean follow-up duration of 9.1 and 8.9 years per person for those who received TNF inhibitors and phototherapy, respectively.

TAKEAWAY:

  • The incidence rate of PsA per 100 patients with psoriasis was 1.18 among those who received TNF inhibitors and 2.48 among those who received phototherapy (incidence rate ratio, 2.1; P = .0002).
  • Treatment with TNF inhibitors was associated with a significantly lower risk for PsA than phototherapy (adjusted hazard ratio [aHR], 0.32; P < .0001), which was noted across different psoriasis severities (on the basis of Psoriasis Area and Severity Index [PASI] scores).
  • Arthralgia was the strongest independent predictor of the risk for PsA (aHR, 7.68; P < .0001), followed by nail psoriasis (aHR, 1.93; P = .0004) and higher baseline PASI scores (aHR, 1.03 per point increase; P = .0096).

IN PRACTICE:

“A multidisciplinary approach involving dermatologists and rheumatologists in identifying and managing arthralgia could be crucial in modifying disease progression,” the authors wrote.

SOURCE:

This study was led by Stefano Piaserico, MD, PhD, Department of Medicine, University of Padua, Padua, Italy. It was published online on July 03, 2025, in Rheumatology.

LIMITATIONS:

Unmeasured confounding factors may have influenced the outcomes. All the patients were recruited from psoriasis referral centres, potentially overrepresenting those with more severe or long-duration disease. Certain TNF inhibitors, such as certolizumab and golimumab, were not included.

DISCLOSURES:

This study did not receive any specific funding. Several authors reported serving as consultants, speakers, and/or advisors for and receiving honoraria from various pharmaceutical companies including AbbVie, Eli Lilly, and Novartis.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.



Source link : https://www.medscape.com/viewarticle/tnf-inhibitors-vs-phototherapy-linked-lower-risk-psa-severe-2025a1000ia9?src=rss

Author :

Publish date : 2025-07-14 12:00:00

Copyright for syndicated content belongs to the linked Source.

Previous Post

HT Amplifies Weight Loss With Tirzepatide in Menopause

Next Post

EU to Ease Clozapine Monitoring Frequency After First Year

Related Posts

Health News

Ed Davey urges US cancer scientists to come to UK

September 22, 2025
Health News

Trump Ties Autism to Tylenol, Warns Pregnant Women of Risk

September 22, 2025
Health News

Private Equity Hospital Acquisition Tied to Uptick in ED Deaths

September 22, 2025
Health News

GLP-1 Drugs Look Good for Psoriasis, Not So Much for Hair

September 22, 2025
Health News

Creeping Fat Drives Scarring in Crohn’s Disease

September 22, 2025
Health News

Previously Rejected Drug Approved as First Barth Syndrome Treatment

September 22, 2025
Load More

Ed Davey urges US cancer scientists to come to UK

September 22, 2025

Trump Ties Autism to Tylenol, Warns Pregnant Women of Risk

September 22, 2025

Private Equity Hospital Acquisition Tied to Uptick in ED Deaths

September 22, 2025

GLP-1 Drugs Look Good for Psoriasis, Not So Much for Hair

September 22, 2025

Creeping Fat Drives Scarring in Crohn’s Disease

September 22, 2025

Previously Rejected Drug Approved as First Barth Syndrome Treatment

September 22, 2025

They ‘Should Not Be Rookies’: Former CDC Officials Raise Concerns About New ACIP

September 22, 2025

Heart-Healthy Eating With a Little Beef Still Beats Average Diet

September 22, 2025
Load More

Categories

Archives

September 2025
MTWTFSS
1234567
891011121314
15161718192021
22232425262728
2930 
« Aug    

© 2022 NewsHealth.

No Result
View All Result
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health

© 2022 NewsHealth.

Go to mobile version